PotterJL, SpectorS, MatthewsLW, LemmJ. The nucleic acids in whole pulmonary secretions from patients with cystic fibrosis, bronchiectasis, and laryngectomy.Am Rev Respir Dis1969; 99: 909–16.
4.
ChernickWS, BarberoGJ. Composition of tracheobronchial secretions in cystic fibrosis of the pancreas and bronchiectasis.Pediatrics1959; 24: 739–45.
5.
American Thoracic Society.A statement by the Committee on Diagnostic Standards for Nontuberculous Respiratory Diseases.Am Rev Respir Dis1962; 85: 762–8.
AitkenML, BurkeW, McDonaldG, ShakS, MontgomeryAB, SmithA. Recombinant human DNase inhalation in normal subjects and patients with cystic fibrosis.JAMA1992; 14: 1947–51.
9.
SalomonA, HerchfusJA, SegalMS. Aerosols of pancreatic dornase in bronchopulmonary disease.Ann Allergy1954; 12: 71–9.
10.
SegalMS, GoldsteinM. Pancreatic dornase aerosols in bronchopulmonary disease.Ann N Y Acad Sci1957; 68: 138–43.
11.
HubbardRC, McElvaneyNG, BirrerP, ShakS, RobinsonWW, JolleyC. A preliminary study of aerosolized recombinant human deoxyribonuclease I in the treatment of cystic fibrosis.N Engl J Med1992; 326: 812–5.
12.
RamseyBW, AstleySJ, AitkenML, BurkeW, ColinAA, DorkinHL. Efficacy and safety of short-term administration of aerosolized recombinant human deoxyribonuclease in patients with cystic fibrosis.Am Rev Respir Dis1993; 148: 145–51.
13.
RanasinhaC, AssoufiB, ShakS, ChristiansenD, FuchsH, EmpeyD. Efficacy and safety of short-term administration of aerosolized recombinant human DNase I in adults with stable stage cystic fibrosisLancet1993; 342: 199–202.
14.
FuchsHG, BorowitzDS, ChristiansenDH, MorrisEM, NashML, RamseyBW. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis.N Engl J Med1994; 331: 637–42.
15.
RamseyBWDorkin HL for the Consensus Committee. Consensus conference: practical application of pulmozyme.Ped Pulmonol1994; 17: 404–8.
WilmottRW, FiedlerMA. Recent advances in the treatment of cystic fibrosis.Ped Clin North Am1994; 41: 431–51.
18.
OsterG, HuseDM, LaceyMJ, ReganMM, FuchsHJ. Effects of recombinant human DNase therapy on healthcare use and costs in patients with cystic fibrosis.Ann Pharmacother1995; 29: 459–64.
19.
ThompsonAB, FuchsH, CorkeryK, PunE, FickRB, RennardSI. Phase II trial of recombinant human DNase for the therapy of chronic bronchitis (abstract).Am Rev Respir Dis1993; 147(4 pt 2): A318.
20.
FickRB, AnzuetoA, MahutteK members of the rhDNase-COPD Study Group. Recombinant DNase mortality reduction in acute exacerbations of chronic bronchitis (abstract).Clin Res1994; 42: 294A.
21.
Medi-Span hospital formulary pricing guide.Indianapolis, IN: Medi-Span, April 1995.
